WuXiTecan-2 technology leads a new strategic collaboration between WuXi XDC Cayman Inc. and Earendil Labs. The partnership focuses on accelerating next-generation antibody-drug conjugate (ADC) development. Moreover, it combines advanced payload-linker chemistry with AI-driven antibody discovery.
Under the agreement, WuXi XDC will grant Earendil Labs an exclusive global license to WuXiTecan-2 technology for multiple targets. In turn, Earendil Labs will use the platform to conjugate antibodies and bispecific antibodies discovered through its AI engine. As a result, both companies aim to move innovative ADC candidates into development faster.
The total potential deal value could reach approximately $885 million. This includes an upfront payment and development milestones. In addition, regulatory and sales milestone payments may apply. WuXi XDC will also receive tiered royalties on net sales if products reach commercialization.
WuXiTecan-2 Technology Strengthens ADC Innovation
WuXiTecan-2 technology enhances payload stability and therapeutic precision. Therefore, it helps improve the safety and effectiveness of ADC candidates. Furthermore, the platform supports scalable and efficient development.
WuXi XDC will provide full CRDMO support. This includes Chemical, Manufacturing, and Controls (CMC) development. It also covers manufacturing of ADC components. Consequently, Earendil Labs can focus on clinical progress and global regulatory submissions.
Meanwhile, Earendil Labs will lead product development and commercialization strategy. This clear division of responsibilities ensures efficient execution. As a result, both partners can accelerate timelines.
AI and CRDMO Integration for Faster Development
The collaboration highlights the growing role of AI in biologics research. Earendil Labs uses AI to discover differentiated bispecific and multi-specific antibodies. When combined with WuXiTecan-2 technology, these candidates may show improved clinical performance.
Importantly, integrating AI discovery with a global CRDMO platform reduces development complexity. In addition, it supports faster manufacturing readiness. Therefore, the partnership may improve the success rate of next-generation ADC programs.
Future Outlook
Demand for targeted biologics continues to rise. Consequently, platforms like WuXiTecan-2 technology may become central to ADC innovation. The collaboration strengthens WuXi XDC’s global ADC capabilities. At the same time, it advances Earendil Labs’ mission to transform biopharmaceutical R&D through AI.
Ultimately, by aligning AI-driven antibody discovery with integrated manufacturing expertise, the companies aim to deliver innovative therapies to patients worldwide.
Read Also: PNCC Selects LotusFlare to Power 4G/5G Standalone Digital BSS Platform
